首页> 美国卫生研究院文献>Medical Journal Armed Forces India >Favipiravir: A new and emerging antiviral option in COVID-19
【2h】

Favipiravir: A new and emerging antiviral option in COVID-19

机译:Favipiravir:Covid-19中的一个新的和新兴抗病毒选择

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.
机译:从全球报告的超过1600万个案例中,SARS-COV-2只有125微米直径,对我们的世界留下了不可磨灭的影响。随着新药物的缺乏对抗这种疾病,医学界是在一场比赛中,以确定可对这种新型冠状病毒有效的重新培养药物。最近赢得了很多关注的药物之一,特别是在印度,是最初为流感而设计的抗病毒药物,称为Favipiravir。在本文中,我们试图在目前大流行的背景下提供对该药物的全面,循证审查,以阐明其在Covid-19管理中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号